IP Library Granted Patent US 11,286,514
Granted Patent B1
US 11,286,514 · App. 17/072,502 · Granted Mar 29, 2022

T5 exonuclease-based method to identify DNA topoisomerase inhibitors

Inventors: Fenfei Leng (Palmetto Bay, FL); Zifang Deng (Miami, FL)
Assignee: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
C12Q1/533C12Q1/44G01N21/6428G01N2021/6439G01N2500/04G01N2500/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,286,514
App. No.
17/072,502
Granted
Mar 29, 2022
Kind
B1
Abstract

The present invention provides assays and methods for studying DNA topology and topoisomerases. The assays and methods utilize a circular plasmid DNA comprising one or more hairpin structures and the ability of T5 exonuclease (T5E) to digest the circular plasmid DNA in a specific configuration. The assays and methods can be used as a high throughput screening for inhibitors of, for example, DNA gyrases and DNA topoisomerases I for anticancer drug and antibiotics discovery.

Claims (12)

1. A method for identifying an inhibitor targeting a DNA topoisomerase type I in a sample, the method comprising adding a circular double-stranded plasmid comprising two hairpin structures upon supercoiling from a relaxed configuration, wherein the circular double-stranded plasmid does not comprise a fluorescent dye; adding the DNA topoisomerase; adding a T5 exonuclease (T5E); adding a DNA-staining dye; and determining the presence or absence of the inhibitor based on fluorescence in the sample.

2. The method of claim 1 , the DNA topoisomerase being bacterial DNA topoisomerase I, human DNA topoisomerase I, or virus DNA topoisomerase I.

3. The method of claim 2 , the bacterial DNA topoisomerase I being E. coli TopoI, or MtbTopoI.

4. The method of claim 1 , the circular double-stranded plasmid being pAB1.

5. The method of claim 1 , the circular double-stranded plasmid comprising an adenosine-thymidine dinucleotide repeat (AT)n sequence, wherein n=21.

6. The method of claim 1 , the circular double-stranded plasmid comprising at least one DNA endonuclease recognition site.

7. The method of claim 1 , which comprises adding a circular double-stranded plasmid comprising an adenosine-thymidine dinucleotide repeat (AT)n sequence, n=21; and determining the presence or absence of the inhibitor based on the fluorescence in the sample, wherein a lower fluorescence in the sample than a control is indicative of the presence of the inhibitor of the DNA topoisomerase type I, wherein the control comprises the circular supercoiled double-stranded plasmid in a relaxed conformation.

8. The method of claim 1 , which further comprises adding ATP in the sample.

9. The method of claim 1 , which comprises incubating T5E in the sample for at least 1 hour prior to adding the DNA-staining dye.

10. The method of claim 1 , the sample being a sample in a high throughput screening (HTS) sample carrier.

11. The method of claim 1 , the DNA topoisomerase I being human topoisomerase I and the inhibitor being NSC668394.

12. The method of claim 1 , the DNA-staining dye being Hoechest 33258, SYBR gold, ethidium bromide, EthD-1, or SYBR green.

Assignments (2)
CONFIRMATORY LICENSE Recorded Oct 26, 2023
From: FLORIDA INTERNATIONAL UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 065365/0520 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2021
From: LENG, FENFEI; DENG, ZIFANG
To: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
Reel/Frame 054810/0168 →